Zymeworks Inc

NYSE:ZYME   9:46:48 AM EDT
-0.30 (-0.83%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.66B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$9.7 Million
Adjusted EPS-$1.26
See more estimates
10-Day MA$33.79
50-Day MA$33.54
200-Day MA$37.12
See more pivots

Zymeworks Inc Stock, NYSE:ZYME

1385 West 8th Avenue, Suite 540, Vancouver, British Columbia V6H 3V9
Phone: +1.604.678.1388
Number of Employees: 355


Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.